Open AccessJournal Article
Nonsteroidal Anti-Inflammatory Drugs and Hypertension.
TLDR
Certain drugs (e.g., indomethicin, piroxicam, and naproxen) may cause clinically relevant elevations in blood pressure in hypertensive patients, and these drugs may affect blood pressure by inhibiting prostaglandin synthesis, which may affect arteriolar smooth muscle tone and natriuresis.Abstract:
Nonsteroidal anti-inflammatory drugs are among the most widely prescribed medications. Their effect on blood pressure has been monitored, and many small studies have determined a potential relationship between their use and elevation of blood pressure. These drugs may affect blood pressure by inhibiting prostaglandin synthesis, which may affect arteriolar smooth muscle tone and natriuresis. Since many patients with conditions such as osteoarthritis require treatment and also have hypertension, even modest elevations in blood pressure or inhibition of antihypertensive medication efficacy resulting from non steroidal anti-inflammatory drugs can be of significant clinical and public health importance. This review finds that certain drugs (e.g., indomethicin, piroxicam, and naproxen) may cause clinically relevant elevations in blood pressure in hypertensive patients. Aspirin and sulindac do not appear to elevate blood pressure significantly, even in hypertensive patients. Ibuprofen and other nonsteroidal anti-inflammatory drugs appear to have an intermediate blood pressure effect. Cyclo-oxygenase-2 inhibitors such as refecoxib and celecoxib have been shown to cause mild elevations in blood pressure, but further studies are needed to evaluate the full magnitude and population distribution of this effect. (c)2000 by Le Jacq Communications, Inc.read more
Citations
More filters
Journal ArticleDOI
Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations.
Cheuk-Chun Szeto,Kentaro Sugano,Ji-Guang Wang,Kazuma Fujimoto,Samuel L Whittle,Samuel L Whittle,Gopesh K Modi,Chen-Huen Chen,Jeong-Bae Park,Lai-Shan Tam,Lai-Shan Tam,Kriengsak Vareesangthip,Kelvin K.F. Tsoi,Francis K.L. Chan +13 more
TL;DR: NSAIDs are a valuable armamentarium in clinical medicine, but appropriate recognition of high-risk cases, selection of a specific agent, choice of ulcer prophylaxis and monitoring after therapy are necessary to minimise the risk of adverse events.
Journal ArticleDOI
Indomethacin impairs mitochondrial dynamics by activating the PKCζ-p38-DRP1 pathway and inducing apoptosis in gastric cancer and normal mucosal cells
Somnath Mazumder,Rudranil De,Subhashis Debsharma,Samik Bindu,Pallab Maity,Souvik Sarkar,Shubhra Jyoti Saha,Asim Azhar Siddiqui,Chinmoy Banerjee,Shiladitya Nag,Debanjan Saha,Saikat Pramanik,Kalyan Mitra,Uday Bandyopadhyay +13 more
TL;DR: In this paper, the subcellular mechanism by which nonsteroidal anti-inflammatory drugs induce apoptosis in gastric cancer and normal mucosal cells is elusive because of the diverse cyclooxygenase-independent effects of these drugs.
Journal ArticleDOI
Selecting nonprescription analgesics
TL;DR: Despite the possibility of hepatotoxicity in overdose, paracetamol represents a better all-round option for most patients requiring OTC analgesic therapy, and is the simple analgesic drug of first choice.
Journal ArticleDOI
Areas of emerging interest in analgesia: cardiovascular complications.
TL;DR: The impact on the cardiovascular system of different classes of analgesics (NSAIDs, the new cyclooxygenase-2-selective inhibitors [CSIs], and paracetamol) in terms of cardiac function, thrombotic and cardioprotective potential, and hypertension is discussed.
Journal ArticleDOI
A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
TL;DR: Results show that COx-2 inhibitors are being prescribed for patients with multiple risk factors that may place the patient at increased risk of adverse drug reactions to a COX-2 inhibitor.